Display options
Cite
Kang HS, Kim YH, Lee CS, et al. Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm. 1996;5(4):280-91doi: 10.1155/S0962935196000415.
Kang, H. S., Kim, Y. H., Lee, C. S., Lee, J. J., Choi, I., & Pyun, K. H. (1996). Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators of inflammation, 5(4), 280-91. https://doi.org/10.1155/S0962935196000415
Kang, H S, et al. "Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models." Mediators of inflammation vol. 5,4 (1996): 280-91. doi: https://doi.org/10.1155/S0962935196000415
Kang HS, Kim YH, Lee CS, Lee JJ, Choi I, Pyun KH. Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm. 1996;5(4):280-91. doi: 10.1155/S0962935196000415. PMID: 18475741; PMCID: PMC2365809.
Copy Download .nbib Format: NLM
Share it on

Mediators Inflamm. 1996;5(4):280-91. doi: 10.1155/S0962935196000415.

Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models.

Mediators of inflammation

H S Kang, Y H Kim, C S Lee, J J Lee, I Choi, K H Pyun

Affiliations

  1. Immune Cell Signal Transduction R.U. Korea Research Institute of Bioscience and Biotechnology KIST Yusong, P.O. Box 115 Taejon 305-600 Korea.

PMID: 18475741 PMCID: PMC2365809 DOI: 10.1155/S0962935196000415

Abstract

Deregulation of interleukin-6 (IL-6) expression caused the synthesis and release of many inflammatory mediators. It is involved in chronic inflammation, autoimmune diseases, and malignancy. Stephania tetrandra S. Moore is a Chinese medicinal herb which has been used traditionary as a remedy for neuralgia and arthritis in China. To investigate the anti-inflammatory effects of S. tetrandra S. Moore in vitro and in vivo, its effects on the production of IL-6 and inflammatory mediators were analysed. When human monocytes/macrophages stimulated with silica were treated with 0.1-10 mug/ml S. tetranda S. Moore, the production of IL-6 was inhibited up to 50%. At these concentrations, it had no cytotoxicity effect on these cells. It also suppressed the production of IL-6 by alveolar macrophages stimulated with silica. In addition, it inhibited the release of superoxide anion and hydrogen peroxide from human monocytes/macrophages. To assess the anti-fibrosis effects of S. tetrandra S. Moore, its effects on in vivo experimental inflammatory models were evaluated. In the experimental silicosis model, IL-6 activities in the sera and in the culture supernatants of pulmonary fibroblasts were also inhibited by it. In vitro and in vivo treatment of S. tetrandra S. Moore reduced collagen production by rat lung fibroblasts and lung tissue. Also, S. tetrandra S. Moore reduced the levels of serum GOT and GPT in the rat cirrhosis model induced by CCL(4), and it was effective in reducing hepatic fibrosis and nodular formation. Taken together, these data indicate that it has a potent anti-inflammatory and antifibrosis effect by reducing IL-6 production.

References

  1. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4068-72 - PubMed
  2. Anal Biochem. 1980 Jul 1;105(2):424-9 - PubMed
  3. J Exp Med. 1988 Mar 1;167(3):1253-8 - PubMed
  4. Lung. 1986;164(3):139-54 - PubMed
  5. Clin Exp Immunol. 1994 Mar;95(3):530-5 - PubMed
  6. J Immunol. 1985 Sep;135(3):2069-73 - PubMed
  7. Immunol Today. 1991 May;12(5):143-6 - PubMed
  8. Eur J Immunol. 1988 Nov;18(11):1797-801 - PubMed
  9. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6367-71 - PubMed
  10. Arthritis Rheum. 1990 Mar;33(3):398-402 - PubMed
  11. Proc Natl Acad Sci U S A. 1988 Sep;85(18):6701-5 - PubMed
  12. Eur J Immunol. 1992 Aug;22(8):1989-93 - PubMed
  13. Int Arch Allergy Appl Immunol. 1988;85(4):410-5 - PubMed
  14. Cancer Res. 1988 Feb 1;48(3):589-601 - PubMed
  15. Immunol Today. 1990 Dec;11(12):443-9 - PubMed
  16. Immunol Today. 1991 Jan;12(1):17-23 - PubMed
  17. J Clin Invest. 1989 Dec;84(6):2008-11 - PubMed
  18. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9679-83 - PubMed
  19. Mol Cell Biol. 1988 Aug;8(8):3546-9 - PubMed
  20. J Exp Med. 1988 Sep 1;168(3):879-90 - PubMed
  21. J Clin Invest. 1990 Jun;85(6):1833-43 - PubMed
  22. J Immunol. 1982 May;128(5):2177-82 - PubMed

Publication Types